Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Gene editing for the development of CAR-T cells
Company stage: Clinical
Diseases: Haematological cancers and solid tumours
Genome editing tool: ARCUS genome-editing platform (licensed from Precision Biosciences), TALEN (Cellectis/Allogene Therapeutics)
Funding stage: Private
Location: Suresnes, France
Servier is a privately held, France-based, international big pharma company. The company has been in operation since 1954, and employs around 20,000 employees today. The company has established several contracts with high profile gene therapy companies, including a CAR-T development deal with Precision Biosciences and an allogeneic CAR-T deal with Allogene Therapeutics.